The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trial

  • James M. Kilgour
  • , Hal Landy
  • , Alexa B. Kimball
  • , Barry I. Resnik
  • , Milan J. Anadkat
  • , Sunil Dhawan
  • , Mark de Souza
  • , Kavita Y. Sarin

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)365-368
Number of pages4
JournalJournal of the American Academy of Dermatology
Volume94
Issue number1
DOIs
StatePublished - Jan 2026

Keywords

  • NLRP3
  • P2X7
  • clinical trials
  • hidradenitis suppurativa
  • immune exhaustion

Cite this